STOCK TITAN

NUMINUS WELLNESS INC - NUMIF STOCK NEWS

Welcome to our dedicated page for NUMINUS WELLNESS news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on NUMINUS WELLNESS stock.

Numinus Wellness Inc. (NUMIF) is a mental health care company dedicated to advancing traditional and innovative behavioral health treatments through safe, evidence-based psychedelic-assisted therapies. They aim to heal rather than manage symptoms of depression, anxiety, trauma, pain, and substance use. By leading the integration of psychedelic-assisted therapies into mainstream clinical practice, Numinus is pioneering a healthier society. Numinus helps individuals heal and be well by providing innovative mental health care and access to safe, evidence-based therapies.

Rhea-AI Summary

On June 7, 2024, Numinus Wellness commented on the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) meeting on June 4, 2024, which reviewed Lykos Therapeutics' new drug application for MDMA-assisted therapy for PTSD. The PDAC voted against recommending approval, with 2 of 11 members supporting MDMA's effectiveness and 1 member acknowledging its benefits outweighing risks. The FDA is expected to decide in August 2024, with historical data showing a 33% approval rate for drugs not recommended by PDAC. Numinus remains optimistic and continues to focus on other clinical treatments like Spravato and ketamine, aiming to achieve profitability with current operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
-
Rhea-AI Summary

Numinus Wellness announced the results from its annual general meeting held on May 31, 2024. Approximately 15.68% of the company's common shares were represented at the meeting. Six nominees were elected as directors with significant majority votes: Payton Nyquvest (86.16%), Allen Morishita (76.45%), Larry Timlick (94.43%), Michael Tan (85.06%), Donna Wong (95.87%), and Donna Wilson (95.87%). All proposed resolutions, including setting the number of directors at six and appointing Davidson & Company LLP as auditors, were approved. Detailed voting results are available on SEDAR+.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary

Numinus Wellness has announced a strategic blueprint aimed at enhancing its presence in the U.S. and accelerating its path to profitability. The company plans to optimize costs and expand its network of wellness clinics and clinical research facilities. Key initiatives include a comprehensive membership program and a partnership with the Canadian Centre for Psychedelic Healing (Field Trip Health). This collaboration involves transitioning Numinus' Canadian therapists to Field Trip Health, closing clinics in Montreal, Toronto, and Vancouver, and leasing space for clinical trials at Field Trip Health's Vancouver clinic. The companies have also signed a 3-year training and marketing agreement to further their common interests. The plan emphasizes scalable growth, shareholder returns, and broader access to psychedelic-assisted therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
Rhea-AI Summary

Numinus Wellness has announced its Cedar Clinical Research (CCR) site has been selected for Cybin's Phase 3 clinical trial of CYB003 for Major Depressive Disorder (MDD). The trial, set to begin enrollment mid-2024, follows promising Phase 2 results where 75% of participants achieved remission from depression symptoms. The U.S. FDA has granted breakthrough therapy designation for CYB003. The Murray, Utah location is among the 15 U.S. sites chosen for the study. Dr. Paul Thielking will lead the trial as Principal Investigator. This partnership aims to advance psychedelic-assisted therapy and address unmet needs in mental health care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
-
Rhea-AI Summary

Numinus Wellness (TSX: NUMI, OTCQX: NUMIF), a mental health care company focused on psychedelic-assisted therapies, has received Health Canada approval for a new study. The trial will explore the feasibility of a group model for MDMA-assisted psychotherapy, aiming to determine the optimal number of therapists needed for group sessions. The study will involve trainee practitioners who will gain core competencies by observing seasoned therapists and experiencing MDMA in a therapeutic setting. This research aims to enhance the understanding of administering MDMA for severe mental disorders like PTSD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
-
Rhea-AI Summary

Numinus Wellness Inc. announces a strategic plan to focus on U.S. operations for higher growth and profitability. The company is enhancing its wellness clinics and clinical research facilities, launching a membership program for healthcare professionals in psychedelic-assisted therapies, and collaborating with Field Trip Health. Numinus also entered into an agreement with Field Trip Health to transition Canadian clinic operations, aiming to optimize therapy and training expertise while maximizing shareholder returns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.43%
Tags
none
Rhea-AI Summary
Numinus Wellness Inc. announces Cedar Clinical Research as a site for Cybin's Phase 3 trial of CYB003 for Major Depressive Disorder. In Phase 2, 75% of patients achieved remission from depression symptoms. The FDA granted CYB003 breakthrough therapy designation. Phase 3 enrollment starts mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.08%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. provides a corporate update focusing on streamlining operations, maximizing shareholder returns, expanding Psychedelic Assisted Therapy training, and exploring opportunities to redefine, divest, or discontinue Canadian clinical operations. The company sharpens its focus on growth opportunities in the U.S. while maintaining support for Canadian organizations and healthcare professionals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.03%
Tags
none
-
Rhea-AI Summary
Numinus Wellness Inc. reported Q2 Fiscal 2024 results with a cash position of $6.6 million, a gross profit of $0.5 million, and revenue of $5.0 million. The company doubled enrolment in training programs, managed 15 clinical trials, and provided 17,661 client appointments. Numinus submitted a Clinical Trial Application to Health Canada for MDMA-assisted psychotherapy. Despite revenue and gross margin declines, the company focused on profitability and cost containment measures. Operational highlights include revenue decline in wellness clinics, clinical research revenues, and clinical training program success. Corporate updates included key appointments and retirements. Numinus ended the quarter with $6.6 million in cash and a positive outlook for growth in the psychedelic sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.03%
Tags
Rhea-AI Summary
Numinus Wellness Inc. to release financial results for Q2 2024 on April 15, 2024. The company focuses on psychedelic-assisted therapies for mental health care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
conferences earnings

FAQ

What is the current stock price of NUMINUS WELLNESS (NUMIF)?

The current stock price of NUMINUS WELLNESS (NUMIF) is $0.02605 as of December 24, 2024.

What is the market cap of NUMINUS WELLNESS (NUMIF)?

The market cap of NUMINUS WELLNESS (NUMIF) is approximately 10.9M.

What is Numinus Wellness Inc. focused on?

Numinus Wellness Inc. is dedicated to advancing mental health care through traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies.

What is Numinus Wellness Inc.'s mission?

Numinus Wellness Inc. aims to heal rather than manage symptoms for various mental health conditions such as depression, anxiety, trauma, pain, and substance use by integrating psychedelic-assisted therapies into mainstream clinical practice.

How does Numinus Wellness Inc. contribute to mental health care?

Numinus Wellness Inc. provides innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies, leading to healing and well-being for individuals.

What sets Numinus Wellness Inc. apart from other mental health care providers?

Numinus Wellness Inc. distinguishes itself by promoting healing through psychedelic-assisted therapies rather than symptom management, pioneering a healthier society.

What is the goal of Numinus Wellness Inc. in the mental health care space?

Numinus Wellness Inc. aims to integrate psychedelic-assisted therapies into mainstream clinical practice, transforming mental health care and building a foundation for a healthier society.

NUMINUS WELLNESS INC

OTC:NUMIF

NUMIF Rankings

NUMIF Stock Data

10.90M
309.90M
3.85%
2.67%
Medical Care Facilities
Healthcare
Link
United States of America
Vancouver